Trexquant Investment LP Kezar Life Sciences, Inc. Transaction History

Trexquant Investment LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.13 - $7.31 $27,553 - $64,349	-8,803 Reduced 37.45%	14,704 $46,000
Q4 2022 Feb 13, 2023	SELL	$6.39 - $8.8 $276,188 - $380,353	-43,222 Reduced 64.77%	23,507 $165,000
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $251,349 - $338,173	-31,458 Reduced 32.04%	66,729 $575,000
Q2 2022 Aug 11, 2022	BUY	$4.58 - $17.13 $285,453 - $1.07 Million	62,326 Added 173.8%	98,187 $812,000
Q1 2022 May 13, 2022	BUY	$12.3 - $18.33 $173,196 - $258,104	14,081 Added 64.65%	35,861 $596,000
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $41,976 - $94,334	5,642 Added 34.96%	21,780 $364,000
Q3 2021 Nov 12, 2021	BUY	$4.85 - $9.73 $9,472 - $19,002	1,953 Added 13.77%	16,138 $139,000
Q2 2021 Aug 12, 2021	BUY	$4.93 - $6.46 $69,932 - $91,635	14,185 New	14,185 $77,000
Q3 2020 Nov 06, 2020	SELL	$4.36 - $5.5 $223,676 - $282,161	-51,302 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$3.6 - $7.75 $184,687 - $397,590	51,302 New	51,302 $266,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $510M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.